I was diagnosed with HGSOC in January, 1999. I have been taking Zejula since I finished chemo in October, 1999. I was first put on 300mg and within 2 months had a drastic drop in platelets. I was then put on 200mg and have been on it since then, tolerating it well. My oncologist is suggesting that I discontinue, but that's not my choice. So far, my scans and CA125 tests show no sign of recurrence....
Mary | 65-74 | Female | On medication for 2 to less than 5 years | Patient
4/21/2023
Condition: Cancer of Fallopian Tube
Overall rating 4.7
Effectiveness
Ease of Use
Satisfaction
I was diagnosed with HGSOC in January, 1999. I have been taking Zejula since I finished chemo in October, 1999. I was first put on 300mg and within 2 months had a drastic drop in platelets. I was then put on 200mg and have been on it since then, tolerating it well. My oncologist is suggesting that I discontinue, but that's not my choice. So far, my scans and CA125 tests show no sign of recurrence.
Faith, prayers from all over and GSK have saved my life and I am truly thankful.
1
Report this post
Thresa | 55-64 | Female | On medication for 1 to 6 months | Patient
7/22/2021
Condition: Primary Cancer of Peritoneum
Overall rating 1.0
Effectiveness
Ease of Use
Satisfaction
I certainly hoped that Zejula would work for me and I sincerely hope that it works for others, but that was not my experience. Within a month and a half I had to have a blood transfusion because it attacked my red blood cells. It caused my glucose levels to go up and drove my blood pressure to dangerously high levels. I simply couldn't tolerate it and I tolerated chemotherapy very well.
IMPORTANT INFORMATION ABOUT USER-GENERATED CONTENT ON WEBMD
The opinions expressed in WebMD User-generated content areas like communities, reviews, ratings, or blogs are solely those of the User, who may or may not have medical or scientific training. These opinions do not represent the opinions of WebMD. User-generated content areas are not reviewed by a WebMD physician or any member of the WebMD editorial staff for accuracy, balance, objectivity, or any other reason except for compliance with our Terms and Conditions.